It has been about a month since the last earnings report for Morgan Stanley (MS) . Shares have added about 3.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Morgan Stanley due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.Morgan Stanley Q3 Earnings Beat on Deal-Making Bo ...

A month has gone by since the last earnings report for Synchrony (SYF) . Shares have added about 5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Synchrony due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Synchrony Financial before we dive into how investors and analysts have reacted as of late.Synchrony Q3 Earnings Beat Estimat ...

Forge Global Holdings, Inc. (FRGE) reported $21.26 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 10.6%. EPS of -$1.35 for the same period compares to -$1.50 a year ago.The reported revenue represents a surprise of -20.52% over the Zacks Consensus Estimate of $26.75 million. With the consensus EPS estimate being -$1.01, the EPS surprise was -33.66%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled, suggesting the need to disable it for a better experience [1]

Core Insights - Jefferson Capital, Inc. (JCAP) reported revenue of $150.84 million for the quarter ended September 2025, showing no year-over-year change, with an EPS of $0.74 compared to $0 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $147.29 million by 2.41%, and the EPS surpassed the consensus estimate of $0.64 by 15.63% [1] Financial Performance Metrics - Total collections for the quarter were $236.8 million, slightly below the average estimate of $242.47 million from two analysts [4] - Servicing revenue was reported at $9.41 million, compared to the average estimate of $10.5 million from two analysts [4] - Total portfolio revenue reached $139.67 million, exceeding the estimated $135.09 million from two analysts [4] Stock Performance - Shares of Jefferson Capital, Inc. have returned +11.5% over the past month, outperforming the Zacks S&P 500 composite's +4.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Performance - Veeva Systems (VEEV) closed at $291.70, down 1.77% from the previous trading session, underperforming compared to the S&P 500's loss of 1.66% [1] - The stock has increased by 3.33% over the past month, which is lower than the Medical sector's gain of 6.4% and the S&P 500's gain of 4.64% [1] Upcoming Earnings - Veeva Systems is set to release its earnings report on November 20, 2025, with projected earnings of $1.95 per share, reflecting a year-over-year growth of 11.43% [2] - The consensus estimate for quarterly revenue is $791.88 million, indicating a 13.25% increase from the same period last year [2] Full Year Estimates - For the full year, earnings are projected at $7.78 per share and revenue at $3.14 billion, showing increases of 17.88% and 14.26% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Veeva Systems are closely monitored, as positive revisions indicate optimism about the business outlook [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Veeva Systems at 2 (Buy) [5] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 38.18, which is higher than the industry average of 34.81 [5] - The company has a PEG ratio of 1.63, compared to the Medical Info Systems industry's average PEG ratio of 3.09 [6] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [6][7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

A month has gone by since the last earnings report for Goldman Sachs (GS) . Shares have added about 9.3% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Goldman due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.Goldman Q3 Earnings Beat Es ...

Core Viewpoint - Johnson & Johnson's recent earnings report shows strong performance with earnings and sales exceeding estimates, but the company faces challenges from product exclusivity losses and competition in certain segments [2][3][22]. Financial Performance - Q3 2025 earnings were $2.80 per share, beating the Zacks Consensus Estimate of $2.77, and reflecting a 15.7% increase year-over-year [2]. - Reported earnings, including special items, were $2.12 per share, up 91% year-over-year [2]. - Sales reached $24.0 billion, surpassing the Zacks Consensus Estimate of $23.74 billion, with a 6.8% increase from the previous year [2][3]. Sales Breakdown - Domestic sales rose 6.2% to $13.7 billion, while international sales increased 7.6% to $10.3 billion [4]. - The Innovative Medicines segment saw sales rise 6.8% to $15.56 billion, driven by key products like Darzalex and Tremfya [5][6]. - The loss of exclusivity for Stelara negatively impacted revenue growth by 640 basis points [3]. Segment Performance - Oncology sales, particularly for Darzalex, grew 21.7% to $3.67 billion, while Imbruvica sales declined 7.8% to $695 million due to competitive pressures [8][9]. - Immunology segment sales were affected by Stelara's decline of 41.3% to $1.57 billion, attributed to biosimilar competition [13]. - The MedTech segment reported sales of $8.43 billion, up 6.8%, with strong performance in cardiovascular and surgical products [18][19]. Guidance and Outlook - The company raised its 2025 sales guidance to $93.5 billion-$93.9 billion, indicating growth of 5.4%-5.9% [22]. - Adjusted earnings per share guidance remains at $10.80-$10.90, with operational growth expected to increase by 8.2%-9.2% [24]. - For 2026, J&J anticipates top-line growth exceeding 5%, driven by key products and new launches in both Innovative Medicine and MedTech segments [26][27][28]. Market Position - Johnson & Johnson holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [31].

Core Insights - Honda reported earnings of 60 cents per share for Q2 of fiscal 2026, missing the Zacks Consensus Estimate of 62 cents, but up from 43 cents in the same quarter last year [1] - Quarterly revenues were $35.9 billion, below the Zacks Consensus Estimate of $37.1 billion and down from $36.2 billion year-over-year [1] Segment Performance - The Automobile segment's revenues decreased by 4.6% year-over-year to ¥3.46 trillion ($23.3 billion), with an operating loss of ¥43.4 billion ($292.4 million) compared to an operating income of ¥35.2 billion in the same quarter last year [2] - Motorcycle segment revenues increased by 11% year-over-year to ¥969 billion ($6.53 billion), with an operating profit of ¥179.3 billion ($1.21 billion), up 21% year-over-year [3] - Financial Services segment revenues totaled ¥846.2 billion ($5.7 billion), down 3.3% year-over-year, with an operating profit of ¥58.2 billion ($392 million), down 25% year-over-year [3] - Power Products and Other Businesses generated revenues of ¥100.3 billion ($675 million), up 2% year-over-year, with a narrowed operating loss of ¥78 million compared to ¥3.2 billion in the same period last year [4] Financial Overview and Outlook - As of September 30, 2025, consolidated cash and cash equivalents were ¥4.64 trillion ($31.2 billion), and long-term debt was approximately ¥8.13 trillion ($54.7 billion) [5] - For fiscal 2026, Honda projects consolidated sales volumes of 14.25 million units for Motorcycles, 2.64 million units for Automobiles, and 3.67 million units for Power Products, indicating a 4.1% growth in Motorcycles but declines of 7% and 0.8% in Automobiles and Power Products, respectively [6] - Honda forecasts fiscal 2026 revenues of ¥20.7 trillion, a decline of 4.6% year-over-year, with an operating profit of ¥550 billion, indicating a contraction of 54.7% year-over-year, and a pretax profit forecast of ¥590 billion, suggesting a drop of 55.2% year-over-year [7] Market Position - Honda currently holds a Zacks Rank of 3 (Hold) [8] - Competitors with better rankings include General Motors Company (Rank 1), OPENLANE, Inc. (Rank 1), and Garrett Motion Inc. (Rank 1) [8]